Glutamate transporter SLC1A6 promotes resistance to immunotherapy in cancer

Abstract Background Resistance to immune checkpoint inhibitors remains a significant challenge in the treatment of cancer. Emerging evidence suggests that metabolic reprogramming plays a crucial role in tumor metabolism and progression. Our study strived to investigate the role and underlying mechan...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Chenchen Li, Yi Lin, Haoran Zheng, Hengda Zeng, Longhao Xu, Daqin Wu, Jianwen Lao, Peicong Cai, Shuai Liang, Chunhui Wang, Tianxin Lin, Wenlong Zhong
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer 2025-06-01
Sarja:Cancer Immunology, Immunotherapy
Aiheet:
Cancer treatment
SLC1A6
Immunotherapy
T cells
Linkit:https://doi.org/10.1007/s00262-025-04074-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia